NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Validation of Procedures for Monitoring Crewmember Immune Function SDBI-1900, SMO-015 - Integrated ImmuneThere is ample evidence to suggest that space flight leads to immune system dysregulation. This may be a result of microgravity, confinement, physiological stress, radiation, environment or other mission-associated factors. The clinical risk from prolonged immune dysregulation during space flight are not yet determined, but may include increased incidence of infection, allergy, hypersensitivity, hematological malignancy or altered wound healing. Each of the clinical events resulting from immune dysfunction has the potential to impact mission critical objectives during exploration-class missions. To date, precious little in-flight immune data has been generated to assess this phenomenon. The majority of recent flight immune studies have been post-flight assessments, which may not accurately reflect the in-flight condition. There are no procedures currently in place to monitor immune function or its effect on crew health. The objective of this Supplemental Medical Objective (SMO) is to develop and validate an immune monitoring strategy consistent with operational flight requirements and constraints. This SMO will assess the clinical risks resulting from the adverse effects of space flight on the human immune system and will validate a flight-compatible immune monitoring strategy. Characterization of the clinical risk and the development of a monitoring strategy are necessary prerequisite activities prior to validating countermeasures. This study will determine, to the best level allowed by current technology, the in-flight status of crewmembers immune system. Pre-flight, in-flight and post-flight assessments of immune status, immune function, viral reactivation and physiological stress will be performed. The in-flight samples will allow a distinction between legitimate in-flight alterations and the physiological stresses of landing and readaptation which are believed to alter landing day assessments. The overall status of the immune system during flight (activation, deficiency, dysregulation) and the response of the immune system to specific latent virus reactivation (known to occur during space flight) will be thoroughly assessed. Following completion of the SMO the data will be evaluated to determine the optimal set of assays for routine monitoring of crewmember immune system function, should the clinical risk warrant such monitoring.
Document ID
20070006521
Acquisition Source
Johnson Space Center
Document Type
Conference Paper
Authors
Crucian, Brian
(NASA Johnson Space Center Houston, TX, United States)
Stowe, Raymond
(Detroit Univ. MI, United States)
Mehta, Satish
(NASA Johnson Space Center Houston, TX, United States)
Uchakin, Peter
(Mercer Univ. Macon, GA, United States)
Nehlsen-Cannarella, Sandra
(Detroit Univ. MI, United States)
Morukov, Boris
(Inst. of Biomedical Problems Moscow, Russia)
Pierson, Duane
(NASA Johnson Space Center Houston, TX, United States)
Sams, Clarence
(NASA Johnson Space Center Houston, TX, United States)
Date Acquired
August 24, 2013
Publication Date
January 1, 2007
Subject Category
Aerospace Medicine
Meeting Information
Meeting: NASA JSC 2007 Human Research Program
Location: South Shore Harbor, TX
Country: United States
Start Date: February 12, 2007
End Date: February 14, 2007
Distribution Limits
Public
Copyright
Other

Available Downloads

There are no available downloads for this record.
No Preview Available